Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash & Equivalents (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Cash & Equivalents over the past 3 years, most recently at $207.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $207.6 million for Q4 2025, up 110.21% from a year ago — trailing twelve months through Dec 2025 was $207.6 million (up 110.21% YoY), and the annual figure for FY2025 was $207.6 million, up 110.21%.
  • Cash & Equivalents for Q4 2025 was $207.6 million at Tonix Pharmaceuticals Holding, up from $190.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TNXP hit a ceiling of $207.6 million in Q4 2025 and a floor of $24000.0 in Q3 2024.
  • Median Cash & Equivalents over the past 3 years was $48.9 million (2023), compared with a mean of $72.6 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 99.65% in 2024 and later surged 791795.83% in 2025.
  • Tonix Pharmaceuticals Holding's Cash & Equivalents stood at $25.8 million in 2023, then soared by 282.13% to $98.8 million in 2024, then skyrocketed by 110.21% to $207.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $207.6 million (Q4 2025), $190.1 million (Q3 2025), and $101.5 million (Q2 2025) per Business Quant data.